Immunomedics CEO and leadership

Michael Pehl is a CEO at GEMoaB Monoclonals GmbH and is based in Dresden, Free State of Saxony, Germany. He has worked as General Manager Germany at CELGENE CORP, President and CEO at IMMUNOMEDICS INC, and Senior VP:Global Marketing at CELGENE CORP. Michael works or has worked at Amgen. He attended LMU and Ludwig-Maximilians-University of Munich.

A respected pharmaceutical industry professional, Loretta M. Itri currently serves as Chief Medical Officer at Immunomedics, Inc. where she is responsible for all R&D activities, including Clinical Pharmacology, Regulatory Affairs, Clinical Trials Phases 1-4, Clinical Operations, Drug Safety and Medical Affairs. Prior to this appointment, Dr. Itri was Executive Vice President for Global Health Sciences and Regulatory at The Medicines Company (MDCO) where she was involved in the development of multiple agents, including Inclisiran. Prior to joining MDCO, Loretta Itri was President of Pharmaceutical Development at Genta, Inc. where she played a vital role in the development of therapeutic agents for CLL and breast cancer. Earlier in her career Dr. Itri was Senior Vice President of Medical Affairs at Ortho Biotech, and J&J's Pharmaceutical Research Institute where she led clinical and regulatory activities across all therapeutic areas and oversaw the development of a diverse group of therapeutic agents including Tramadol, Topiramate, Procrit, Levofloxin and Leustatin. She began her pharmaceutical career at Hoffman-LaRoche where she was Assistant Vice President for Oncology and Immunology/Virology and worked extensively on the development of interferons and retinoids.

Dr. Itri received her BS degree magna cum laude from Long Island University and her MD degree from New York Medical College. She undertook residency training at the State University of New York-Stony Brook and an oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC) where she was an adjunct attending physician for more than 15 years. Dr. Itri has twice served as a member of the NCI's Board of Scientific Counselors and has published and lectured extensively on oncology drug development.

Kurt Andrews joined Valeritas as Vice President, Human Resources in July of 2013. Kurt has over 19 years of corporate human resource management experience. Prior to join Valeritas, he was Vice President of Human Resources at PTC Therapeutics, leading the company's Human Resources, Information Technology and Facilities functions. In addition, Kurt was Director of Human Resources at Vitex, a biotechnology company in Boston, and spent seven years in progressive human resources leadership roles at Applera Corporation in California and Boston, supporting the growth of both Applied Biosystems and Celera Genomics. Kurt received an M.A. from the Institute for Labor and Employment Relations at the University of Illinois at Urbana-Champaign and a B.A. from the University of Illinois at Urbana-Champaign.

Vice President, Deputy General Counsel, Chief Compliance Officer & Chief Privacy Officer at Immunomedics

Augusto Penjasoff is an Interim CIO, COO & Sr. Principal Management Consultant at Master Consulting International; CIO & VP Information Technology, Immunomedics (a Gilead Sciences company) at IMMUNOMEDICS INC; and Business Partner, Global Cell Therapy IT Head at Bristol-Myers Squibb and is based in Santa Monica, California. He has worked as Senior System Programmer at Techint, Corporate Director - CIO at IADE American Schools, and Associate Professor. at University Centro de Altos Estudios en Ciencias Exactas. Augusto studied at Universidad Centro de Altos Estudios en Ciencias Exactas between 1985 and 1985, Columbia Business School between 2000 and 2000, and Universidad Centro de Altos Estudios en Ciencias Exactas between 1981 and 1984.

Robert Iannone has been Jazz’s EVP, Research and Development since May 2019. Dr. Iannone oversees product development, clinical operations and regulatory affairs. Dr. Iannone brings more than 16 years of experience in clinical drug development, having worked on immuno-oncology programs at AstraZeneca and its biologics arm MedImmune. He completed his residency in Pediatrics and fellowship in Pediatric Hematology‐Oncology at Johns Hopkins University.